Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Light Ahead for Japanese Bioventures: Mr Yamazaki of IRI
February 28, 2011
- Aloxi Gains Top Share in Antiemetic Market in Just 8 Months: Otsuka
February 28, 2011
- Daiichi Sankyo Acquires US Packaging, Manufacturing Facility
February 28, 2011
- Otsuka Holds Sufficient Stock of IFN from Hayashibara
February 21, 2011
- AZ Stops Multinational PIII Trial of Zibotentan
February 21, 2011
- Astellas Withdraws Application for Darexaban in Japan
February 21, 2011
- Toho Starts New OTC Drugs Sales System Jointly with eHealthcare
February 21, 2011
- Gov't-Industry Dialogue to Resume in March
February 21, 2011
- Introduce “Compendium System”to Solve Problems of Off-label Use: Dr Fujiwara of NCC Hospital
February 21, 2011
- Halaven Approved in Singapore: Eisai
February 21, 2011
- Domestic Production of Drugs Up 3%, Highest in 10 Years
February 21, 2011
- PAFSC to Review Rivastigmine, Edoxaban, Epoetin β Pegol
February 21, 2011
- Chugai Aims to Be No. 1 in Oncology, Nephrology, Bone/Joint Diseases: Mr Nagayama
February 21, 2011
- FDA Adds Actos to List of Drugs with Potential Signals of Serious Risk
February 21, 2011
- DSP to Enhance R&D in Oncology
February 21, 2011
- Sales of Ethical Drugs Down 0.8% in December 2010
February 21, 2011
- Eisai Ties Up with Teikoku Seiyaku for Transdermal Aricept Formulation in Japan
February 21, 2011
- Importance of Close Links between Clinical Trials, Studies Highlighted at Gene Therapy Symposium
February 21, 2011
- Medipal Aims at Sales of ¥3 Tril. in FY2013
February 21, 2011
- Look at New Trends in Emerging Countries: Mr Hasegawa
February 21, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…